Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?

Impact · against what's priced in

The news for Gilead is essentially a confirmation of a trajectory the market has already rewarded with a 38% price surge and all-time highs. No new catalysts were identified that move the needle beyond current valuations for GILD, LLY, or NVDA.

LLY+0.00: Doesn't touch the price's assumptions
In context: The article mentions Eli Lilly only as a performance benchmark for Gilead's stock price growth.
What LLY's price assumes · Sep 10

Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?

What matters in this story

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?

What matters in this story

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

How each ticker is affected

Connected tickers

Track these names every morning.

2 healthcare stocks to turn $10 into $100 by next year

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AppLovin: The Best Part Of Its AI Story May Be Ahead

Medical Properties Trust: I Was Wrong, The Market Is Not (Rating Downgrade)

Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?

What matters in this story

Next reads from the same story arc

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?

What matters in this story

Next reads from the same story arc

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

How each ticker is affected

Connected tickers

Track these names every morning.

2 healthcare stocks to turn $10 into $100 by next year

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AppLovin: The Best Part Of Its AI Story May Be Ahead

Medical Properties Trust: I Was Wrong, The Market Is Not (Rating Downgrade)